共 50 条
- [2] Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome [J]. PharmacoEconomics, 2020, 38 : 1237 - 1245
- [4] Drug therapy in Lennox-Gastaut syndrome [J]. INTRACTABLE SEIZURES: DIAGNOSIS, TREATMENT AND PREVENTION, 2002, 497 : 77 - 86
- [6] Comment on “Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome” [J]. PharmacoEconomics, 2021, 39 : 473 - 475
- [7] ADJUNCTIVE THERAPY OF RUFINAMIDE IN LENNOX-GASTAUT SYNDROME [J]. EPILEPSIA, 2011, 52 : 209 - 209
- [8] ALLOPURINOL AS ADJUNCTIVE THERAPY IN LENNOX-GASTAUT SYNDROME [J]. EPILEPSIA, 1988, 29 (05) : 655 - 656
- [9] Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom [J]. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2010, 19 (01): : 1 - 11
- [10] Adjunctive therapy with levetiracetam in Lennox-Gastaut syndrome [J]. EPILEPSIA, 2004, 45 : 123 - 123